Roche Partner Poseida Touts High Response Rates for Allogeneic CAR-T Therapy

By /

The investigational allogeneic CAR-T therapy P-BCMA-ALLO1 appears to be more effective following strong immunosuppressive preconditioning.

Scroll to Top